Please ensure Javascript is enabled for purposes of website accessibility
Athenex Stock Quote

Athenex (NASDAQ: ATNX)

Price as of May 30, 2023, 3:59 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Athenex Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
ATNX -97.97% -99.94% -77.16% -100%
S&P +3.64% +54.54% +9.08% +72%

Athenex Company Info

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

News & Analysis


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.